Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

ClinicalTrials.gov ID: NCT02475681

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02475681. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil, Acalabrutinib (ACP-196) in Combination With Obinutuzumab, and Acalabrutinib Monotherapy in Subjects With Previously Untreated CLL

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This Primary objective is evaluating the efficacy of obinutuzumab in combination with chlorambucil (Arm A) compared with acalabrutinib in combination with obinutuzumab (Arm B) for the treatment of previously untreated chronic lymphocytic leukemia (CLL). Secondary objectives: 1) To evaluate the efficacy of obinutuzumab in combination with chlorambucil (Arm A) versus acalabrutinib monotherapy (Arm C) based on IRC assessment of PFS per IWCLL 2008 criteria. 2)To compare obinutuzumab plus chlorambucil (Arm A) versus acalabrutinib plus obinutuzumab (Arm B) and obinutuzumab plus chlorambucil (Arm A) versus acalabrutinib monotherapy (Arm C) in terms of: IRC-assessed objective response rate (ORR); Tine to next treatment (TTNT); Overall Survival (OS)

Study identification

NCT ID
NCT02475681
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Acerta Pharma BV
Industry
Enrollment
535 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 26, 2015 (Actual)
Primary completion
Feb 8, 2019 (Actual)
Completion
Sep 3, 2026 (Actual)
Last update posted
Nov 16, 2026

2015 – 2026

United States locations

U.S. sites
51
U.S. states
22
U.S. cities
47
Facility City State ZIP Site status
Research Site Goodyear Arizona 85395 —
Research Site Phoenix Arizona 85016 —
Research Site Anaheim California 92801 —
Research Site Los Angeles California 90017 —
Research Site Los Angeles California 90033 —
Research Site Los Angeles California 90095 —
Research Site Oxnard California 93030 —
Research Site Palo Alto California 94304 —
Research Site Aurora Colorado 80045 —
Research Site Lone Tree Colorado 80124 —
Research Site Washington D.C. District of Columbia 20007 —
Research Site Fort Myers Florida 33901-8101 —
Research Site Jacksonville Florida 32224 —
Research Site Tallahassee Florida 32308-5304 —
Research Site Tallahassee Florida 32308 —
Research Site Tampa Florida 33612 —
Research Site Niles Illinois 60714 —
Research Site Lafayette Indiana 47904 —
Research Site Wichita Kansas 67214 —
Research Site Louisville Kentucky 40207 —
Research Site New Orleans Louisiana 70112 —
Research Site COL Maryland 21044 —
Research Site Rochester Minnesota 55905 —
Research Site Saint Cloud Minnesota 56303 —
Research Site Billings Montana 59102 —
Research Site Brick New Jersey 08724 —
Research Site Hackensack New Jersey ?07601 —
Research Site Lake Success New York 11042 —
Research Site New York New York 10029 —
Research Site Blue Ash Ohio 45242 —
Research Site Canton Ohio 44719 —
Research Site Columbus Ohio 43210 —
Research Site Nashville Tennessee 37203 —
Research Site Austin Texas 78705 —
Research Site Bedford Texas 76022 —
Research Site Dallas Texas 75230 —
Research Site Fort Sam Houston Texas 78234 —
Research Site Houston Texas 77030 —
Research Site New Braunfels Texas 78130 —
Research Site Round Rock Texas 76508 —
Research Site San Antonio Texas 78258 —
Research Site Texas City Texas 77591 —
Research Site Tyler Texas 75702 —
Research Site Salt Lake City Utah 84112 —
Research Site Roanoke Virginia 24014 —
Research Site Seattle Washington 98109 —
Research Site Seattle Washington 98122 —
Research Site Spokane Washington 99208 —
Research Site Tacoma Washington 98405 —
Research Site Yakima Washington 98902 —
Research Site Northwest WA Wisconsin 20007 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 104 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02475681, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 16, 2026 · Synced Nov 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.